Anaphylactic reaction by certolizumab in young woman with rheumatoid arthritis

Anaphylactic reaction by certolizumab in young woman with rheumatoid arthritis

Bibliographic Details
Main Authors:	Elena Urbieta-Sanz, Laura Monteagudo-González, Carmen Caballero-Requejo
Format:	Article
Language:	English
Published:	Grupo Aula Médica 2018-05-01
Series:	Farmacia Hospitalaria
Online Access:	http://www.aulamedica.es/fh/pdf/10914.pdf

Similar Items

Certolizumab pegol in therapy for rheumatoid arthritis
by: Galina Viktorovna Lukina, et al.
Published: (2012-06-01)

Certolizumab pegol (CIMZIA®) for the treatment of rheumatoid arthritis
by: M Connock, et al.
Published: (2010-10-01)

Certolizumab in the long-term treatment of rheumatoid arthritis
by: Scott DL, et al.
Published: (2011-08-01)

QUALITY OF LIFE IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL
by: Vera Nikolayevna Amirdjanova, et al.
Published: (2012-10-01)

Multifocal tuberculosis on certolizumab pegol in a patient followed for rheumatoid arthritis
by: Emna Hannech, et al.
Published: (2021-06-01)

New aspects of the pharmacotherapy of rheumatoid arthritis: a focus on certolizumab pegol
by: Evgeniy L'vovich Nasonov, et al.
Published: (2011-02-01)

New treatment possibilities for rheumatoid arthritis: the Russian experience in using certolizumab pegol
by: Dmitry Evgenyevich Karateev, et al.
Published: (2012-04-01)

Certolizumab Pegol-Induced Folliculitis-Like Lichenoid Sarcoidosis in a Patient with Rheumatoid Arthritis
by: Hiroyuki Sakai, et al.
Published: (2017-09-01)

Prefilled certolizumab pegol (Cimzia&reg;) syringes for self-use in the treatment of rheumatoid arthritis
by: J Rosa, et al.
Published: (2010-08-01)

Real-World Methotrexate Dose on Clinical Effectiveness and Structural Damage of Certolizumab Pegol With Rheumatoid Arthritis
by: Yuji Nozaki, et al.
Published: (2021-04-01)

EFFICACY OF CERTOLIZUMAB PEGOL IN THE TREATMENT OF PSORIATIC ARTHRITIS
by: T. V. Korotaeva, et al.
Published: (2015-10-01)

Exposure–Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients With Rheumatoid Arthritis
by: Stéphane Paul, et al.
Published: (2020-07-01)

The efficacy of certolizumab pegol in rheumatoid arthritis assessed by gray scale and power Doppler ultrasonography: case reports
by: José Alexandre Mendonça, et al.
Published: (2019-02-01)

Certolizumab pegol – new option in the treatment of psoriatic arthritis
by: Maria Majdan, et al.
Published: (2014-07-01)

Profile of certolizumab and its potential in the treatment of psoriatic arthritis
by: Chimenti MS, et al.
Published: (2013-04-01)

Paradoxical Skin Reaction to Certolizumab, an Overlap of Pyoderma Gangrenosum and Psoriasis in a Young Woman Treated for Ankylosing Spondylitis: Case Report with Literature Review
by: Anna Gawdzik, et al.
Published: (2020-05-01)

Predicting the treatment response of certolizumab for individual adult patients with rheumatoid arthritis: protocol for an individual participant data meta-analysis
by: Yan Luo, et al.
Published: (2020-06-01)

Relationship between Lymph Node Volume and Pain following Certolizumab Therapy for Rheumatoid Arthritis Flare: A Pilot Study
by: Homaira Rahimi, et al.
Published: (2016-01-01)

Relationship Between Lymph Node Volume and Pain Following Certolizumab Therapy for Rheumatoid Arthritis Flare: A Pilot Study
by: Homaira Rahimi, et al.
Published: (2016-12-01)

Anaphylactic Reaction to Camomile Tea
by: Christian Andres, et al.
Published: (2009-01-01)

Anaphylactic reactions in anesthetic agents
by: Evangelina Dávila Cabo de Villa
Published: (2019-04-01)

Anaphylactic reactions in anesthetic agents
by: Evangelina Dávila Cabo de Villa
Published: (2019-04-01)

Effectiveness of Certolizumab Pegol in Treating Rheumatoid Arthritis Patients with Persistent Inflamed Residual Mono- or Oligosynovitis Resistant to Prior TNF-α Inhibitors
by: Syuichi Koarada, et al.
Published: (2015-01-01)

Use of a baseline risk score to identify the risk of serious infectious events in patients with rheumatoid arthritis during certolizumab pegol treatment
by: Jeffrey R. Curtis, et al.
Published: (2017-12-01)

THERAPEUTIC APPROACH OF A CASE OF RHEUMATOID ARTHRITIS COMPLICATED WITH RENAL AMYLOIDOSIS IN A YOUNG WOMAN
by: Alexandra Burlui, et al.
Published: (2017-03-01)

Kiss-induced severe anaphylactic reactions
by: Atanasković-Marković Marina, et al.
Published: (2010-01-01)

Anaphylactic reaction in patient allergic to mango
by: Natalia Ukleja-Sokołowska, et al.
Published: (2018-10-01)

Fatal anaphylactic reaction during anesthesia
by: Izidor Kern, et al.
Published: (2012-01-01)

Fatal anaphylactic reaction due to Basiliximab
by: Patricia Lovisolo, et al.
Published: (2017-04-01)

The clinical efficacy and safety of certolizumab pegol (CZP) in the treatment of rheumatoid arthritis: focus on long-term use, patient considerations and the impact on quality of life
by: Roy Fleischmann
Published: (2009-07-01)

An evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: place in therapy
by: Acosta-Felquer ML, et al.
Published: (2016-03-01)

Certolizumab pegol in the treatment of spondyloarthritis
by: Mariusz Korkosz
Published: (2014-09-01)

Anaphylactic Reaction to Pemetrexed: A Case Report
by: Heloise Capelle, et al.
Published: (2014-05-01)

Anaphylactic reaction/angioedema associated with jellyfish sting
by: João Claudio Campos Pereira, et al.

Acute anaphylactic reaction to expired chlorpheniramine injection
by: Beuy Joob, et al.
Published: (2014-01-01)

Anaphylactic reactions to low-molecular weight chemicals
by: Daria Nowak, et al.
Published: (2015-02-01)

Effectiveness and safety of certolizumab pegol in rheumatoid arthritis patients in Canadian practice: 2-year results from the observational FαsT-CAN study
by: Louis Bessette, et al.
Published: (2019-03-01)

A somatization comorbidity phenotype impacts response to therapy in rheumatoid arthritis: post-hoc results from the certolizumab pegol phase 4 PREDICT trial
by: Jeffrey R. Curtis, et al.
Published: (2017-09-01)

Serum TNFα levels at 24 h after certolizumab pegol predict effectiveness at week 12 in patients with rheumatoid arthritis from TSUBAME study
by: Yusuke Miyazaki, et al.
Published: (2021-06-01)

Response to: “A somatization comorbidity phenotype impacts response to therapy in rheumatoid arthritis: post hoc results from the certolizumab pegol phase 4 PREDICT trial”
by: Annelise Madison, et al.
Published: (2019-02-01)

Cannot write session to /tmp/vufind_sessions/sess_mqnpuori5g7kbrgio9jp9k4q3u